Traditionally, bacterial products have been designed around three parameters: strain(s), CFU dosage, and final product form. This mechanistic focus is insufficient – it results in most probiotic products delivering low-survival, passive, plank-tonic form bacteria into gut lumen, with a high (99%+) washout rate within days
The result is the "delivered state" problem: the few surviving bacteria transit through hosts' lumen in dormant, suboptimal functional states, causing low product effectiveness and performance inconsistency. Rather, bacterial products must deliver function-optimised microbial communities pre-adapted to integrate
Imbiome's LB-Platform™ solution unlocks microbial evolutionary intelligence mechanisms to activate two critical efficacy drivers of bacterial products: Bioactivity - microorganisms' ability to integrate into mucosal layer, and Functional State - state of functional gene expression & communal behaviours
Imbiome’s technology pre-adapts and conditions microorganisms to activate microbial evolutionary intelligence — optimising bacterial delivery for performance through (i) mucosal lining integration and (ii) communal functional expression, resulting in faster, more consistent, improved clinical effectiveness. Built on years of validated bacterial physiology & clinical research, LB-Platform™ technology is rooted in three proprietary innovations:
We grow microbes in controlled environments — pre-adapting them to survive real-world biological and environmental stressors, and priming micro-organisms to integrate and function as native colonies
We stimulate key microbial pathways by engaging bacteria with a proprietary nanomatrix — pre-conditioning them for colonisation and functional gene expression needed to form native, integrated microbial communities
High product efficacy results in lower required doses and a lean manufacturing infrastructure – Smart Batch™ Fermentation enables precision-controlled, small-lot manufacturing, with optimal resource use & scalability
LB-Platform™ — a bacterial delivery and functional state optimisation platform technology that produces bioactive, colonisation-ready, and functionally optimised microbes, creating a new category of IP-defensible bacterial products with unmatched performance and breakthrough production economics – across human,
animal, and soil health
LB-Platform™-enabled products consistently deliver superior biological and clinical benefits – unlocking the full potential of live micro-organisms in human health, animal well-being, and soil regeneration applications
LB-Platform™ technology-enabled products have been evaluated in over 40 clinical studies (including 30+ human trials) across diverse populations and health contexts. They consistently demonstrate superior clinical performance and functional outcomes compared to traditional probiotics, antibacterial agents, and baseline therapies — delivering reliable, measurable results across human and animal health applications.
Superior to Antibacterials in Acute Dysbiosis
| Clinical Advantages of Bacterial Products Enabled by LB-Platform™ |
# of Trials with P-significant Results |
|---|---|
| Microbiota Composition/Engraftment | |
| Reduce pathogens | 10 |
| Reduce dysbiosis/increase diversity | 8 |
| More resilient composition | 4 |
| Microbiome Functions | |
| Rebalance metabolites | 5 |
| Improve gut barrier | 3 |
| Reduce inflammation | 3 |
| Renormalize immune function | 5 |
| Restore homeostasis | 4 |
| Clinical Outcomes/Overall Endpoints | |
| Better clinical outcomes | 16 |
| Faster onset of health benefits | 10 |
| Longer effects | 2 |
| Stronger effects | 7 |
Revolutionizing bacterial products with clinically proven probiotics enabled by the proprietary LB-Platform™ technology
